- Carol Ann Satler, MD, PhD, FACC, FAHA, FAAP joins the Board of Directors, adding key clinical experience to guide ongoing nonclinical development in cardiac.
Ashurst Guides PureTech's Proposed $100M Tender Offer miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
VE303 is an orally administered, potential first-in-class live biotherapeutic product candidate being developed to prevent recurrence of Clostridioides difficile infection
.